 | | Vol. 10.32 – 18 August, 2021 |
| |
|
|
| Investigators compared glucose metabolism in hematopoiesis and leukemia. Thymus T cell progenitors were glucose avid and oxidized more glucose in the tricarboxylic acid cycle through pyruvate dehydrogenase as compared with other hematopoietic cells.
[Cell Metabolism] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers investigated whether and how cancer-associated fibroblasts (CAFs) regulates myeloid-derived suppressor cells function to enhance cancer stemness, the driving force of the cancer aggressiveness and chemotherapy refractoriness, in highly desmoplastic intrahepatic cholangiocarcinoma.
[Hepatology] |
|
|
|
| Visceral adipose-derived factors promoted vasculogenesis and the onset of metastatic dissemination by activation of STAT3, which inhibited miR-200a and enhanced ZEB2 expression, effectively reprogramming colorectal cancer cells into a highly metastatic phenotype.
[Nature Communications] |
|
|
|
| Scientists showed that BAZ2A was required for prostate cancer (PCa) cells with a cancer stem-like state. BAZ2A genomic occupancy in PCa cells coincided with H3K14ac-enriched chromatin regions.
[EMBO Reports] |
|
|
|
| Investigators established a novel bladder CSC/cancer-initiating cells (CICs) model from a bladder cancer cell line using an ALDEFLUOR assay. CSCs/CICs were isolated as aldehyde dehydrogenase (ALDH)-high cells and several ALDHhigh clone cells were established.
[Cancer Immunology Immunotherapy] |
|
|
|
| CAR T cells were designed using a ligand binding domain instead of a single chain variable fragments to target stem-like leukemia cells. Thrombopoietin, the natural ligand to the myeloproliferative leukemia protein (MPL) receptor, was used as the antigen binding domain to engage MPL expressed on hematopoeitic stem cells and erythropoietic and megakaryocytic acute myeloid leukemias.
[Gene Therapy] |
|
|
|
| The authors investigated the prognostic significance of T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) in t(8;21) acute myeloid leukemia (AML). A total of 47 t(8;21) AML patients were tested for TIM-3 expression by multi-parameter flow cytometry at diagnosis.
[Leukemia & Lymphoma] |
|
|
|
| Scientists characterized the mechanisms behind prostate CSC-platelet interaction. Fluorescence Activated Cell Sorting was utilized to separate DU145 and PC3 prostate cancer cells into CD133+/CD44+, CD133+/CD44–, CD44+/CD133–, and CD133–/CD44– subpopulations and to measure their CXCR4 surface expression.
[Thrombosis Research] |
|
|
|
| Researchers evaluated platinum-based response in brain tumor U-87 MG, LN-18, and KELLY cell lines cultured in monolayer and neurosphere models as well as mRNA expression of heat shock proteins and DNA repair gene ERCC1.
[Acta Histochemica] |
|
|
|
| Investigators identified chemical inhibitors for seudouridine synthase 7 (PUS7) and showed that these compounds prevented PUS7-mediated pseudouridine modification, suppressed tumorigenesis and extended the life span of tumor-bearing mice.
[Nature Cancer] |
|
|
|
|
| To study cancer cells, single-cell RNA srequencing has provided novel insights into the CSC-like model, treatment resistance, and cancer metastasis.
[Protein & Cell] |
|
|
|
| The authors review the CSC markers that have been previously targeted with CAR-T cells, as well as the CSC markers that may be used as possible targets for CAR-T cell therapy in the future.
[Acta Pharmaceutica Sinica B] |
|
|
|
|
| Biosight Ltd. announced the initiation of a Phase II trial to evaluate aspacytarabine, Biosight’s proprietary antimetabolite, as a second line treatment for patients with relapsed or refractory myelodysplastic syndrome or acute myeloid leukemia.
[Biosight Ltd. (Globe Newswire)] |
|
|
|
| Carrick Therapeutics announced that the US FDA has granted Fast Track designations to samuraciclib in combination with fulvestrant for CDK4/6i resistant HR+, HER2– advanced breast cancer and samuraciclib in combination with chemotherapy for the treatment of locally advanced or metastatic triple-negative breast cancer.
[Carrick Therapeutics] |
|
|
|
|
| October 7 – 11, 2021
Virtual |
|
|
|
|
|
| | Purdue University – West Lafayette, Indiana, United States |
|
|
|
| | Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
| | City of Hope – Duarte, California, United States |
|
|
|
| | Incyte – Wilmington, Delaware, United States |
|
|
|
| | MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
